We are advised by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. that journalists and other readers should disregard the news release, "Third Indication for Kelun-Biotech's TROP2 ADC Sac-TMT Approved for Marketing by NMPA in EGFRm NSCLC Following Progression on EGFR-TKI Therapy", issued 11-Oct-2025 over PR Newswire, as the release contained erroneous information. (Kelunbiotech said a revised release will be issued later. )
source: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
【你點睇？】港交所推每周股票期權新選擇，若能新增一隻作每周股票期權標的，您會選擇哪一隻？► 立即讚好
